首页> 美国卫生研究院文献>Molecules >Microneedle-Assisted Percutaneous Delivery of Paeoniflorin-Loaded Ethosomes
【2h】

Microneedle-Assisted Percutaneous Delivery of Paeoniflorin-Loaded Ethosomes

机译:微针辅助的Pa药苷脂质体经皮递送

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Paeoniflorin, the main component of total glucosides of paeony (TGP), shows good therapeutic effects in arthritis, but has low bioavailability when administered orally. Avoiding such a deficiency for topical administration would expand its clinical application. This study aimed to avoid these limitations by using nanotechnology (ethosomes) and a physical approach (microneedles). Paeoniflorin-loaded ethosomal formulation (TGP-E) was optimized and evaluated in terms of entrapment efficiency (EE), particle size (PS), zeta potential (ZP), polydispersity index (PDI) and morphology. TGP-E was prepared by the hot injection method and optimized by single-factor tests and an orthogonal experimental design. The optimized paeoniflorin-loaded ethosomes had EE of 27.82 ± 1.56%, PS of 137.9 ± 7.57 nm with PDI of 0.120 ± 0.005, ZP of −0.74 ± 0.43 mV. Ethosomes showed a nearly spherical shape under the transmission electron microscope (TEM). The optimal microneedle-assisted (MN-assisted) conditions were obtained at a microneedle length of 500 μm, a pressure of 3 N and an action time of 3 min. The cumulative penetration amounts (Qn) of TGP solution transdermal (ST) and MN-assisted TGP solution transdermal (MST) were 24.42 ± 8.35 μg/cm2 and 548.11 ± 10.49 μg/cm2, respectively. Qn of TGP-E transdermal (PT) and MN-assisted TGP-E transdermal (MPT) were 54.97 ± 4.72 μg/cm2 and 307.17 ± 26.36 μg/cm2, respectively. These findings indicate that use of ethosomes and microneedles can both enhance the penetration ofpaeoniflorin, but for the water-soluble drug, there is no obvious synergism between nanotechnology and microneedles for enhancing penetration in a transdermal drug delivery system.
机译:eon药苷是pa药总苷(TGP)的​​主要成分,对关节炎具有良好的治疗作用,但口服时生物利用度低。避免局部给药的这种不足将扩大其临床应用。这项研究旨在通过使用纳米技术(脂质体)和物理方法(微针)来避免这些限制。优化了药苷载气体制剂(TGP-E),并根据包封率(EE),粒径(PS),ζ电势(ZP),多分散指数(PDI)和形态进行了评估。 TGP-E采用热注射法制备,并通过单因素试验和正交实验设计进行了优化。优化的pa药苷负载的脂质体的EE为27.82±1.56%,PS为137.9±7.57 nm,PDI为0.120±0.005,ZP为-0.74±0.43 mV。在透射电子显微镜(TEM)下,脂质体显示出接近球形的形状。在500μm的微针长度,3 N的压力和3分钟的作用时间下获得了最佳的微针辅助(MN辅助)条件。 TGP溶液透皮(ST)和MN辅助的TGP溶液透皮(MST)的累积渗透量(Qn)为24.42±8.35μg/ cm 2 和548.11±10.49μg/ cm 2 。 TGP-E透皮(PT)和MN辅助的TGP-E透皮(MPT)的Qn分别为54.97±4.72μg/ cm 2 和307.17±26.36μg/ cm 2 , 分别。这些发现表明,使用脂质体和微针都可以增强pa药苷的渗透性,但是对于水溶性药物,纳米技术和微针之间没有明显的协同作用以增强透皮给药系统的渗透性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号